Long-Term Efficacy of Single-Agent Vemurafenib for Pleomorphic Xanthoastrocytoma

Elizabeth A. Finch; Scott W. Elton; Benjamin Y. Huang; Dimitri G. Trembath; Julie Blatt

doi:10.1097/MPH.0000000000001395

Long-Term Efficacy of Single-Agent Vemurafenib for Pleomorphic Xanthoastrocytoma

Elizabeth A. Finch, Scott W. Elton, Benjamin Y. Huang, Dimitri G. Trembath, Julie Blatt

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAF V600E mutations are common in pleomorphic xanthoastrocytomas and provide an additional means for treatment when excision is not possible. Monotherapy with the BRAF V600E inhibitor vemurafenib has only been reported in a small number of cases and mostly in adults. We present the case of a 16-year-old male who responded to vemurafenib monotherapy initially and had an additional response to vemurafenib following progression after a brief time off the medication.

Original language	English (US)
Pages (from-to)	152-155
Number of pages	4
Journal	Journal of pediatric hematology/oncology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1097/MPH.0000000000001395
State	Published - Mar 1 2020

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000001395

Cite this

@article{ea027f8e026449fe97a76139483af416,

title = "Long-Term Efficacy of Single-Agent Vemurafenib for Pleomorphic Xanthoastrocytoma",

abstract = "Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAF V600E mutations are common in pleomorphic xanthoastrocytomas and provide an additional means for treatment when excision is not possible. Monotherapy with the BRAF V600E inhibitor vemurafenib has only been reported in a small number of cases and mostly in adults. We present the case of a 16-year-old male who responded to vemurafenib monotherapy initially and had an additional response to vemurafenib following progression after a brief time off the medication.",

author = "Finch, {Elizabeth A.} and Elton, {Scott W.} and Huang, {Benjamin Y.} and Trembath, {Dimitri G.} and Julie Blatt",

year = "2020",

month = mar,

day = "1",

doi = "10.1097/MPH.0000000000001395",

language = "English (US)",

volume = "42",

pages = "152--155",

journal = "Journal of pediatric hematology/oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Long-Term Efficacy of Single-Agent Vemurafenib for Pleomorphic Xanthoastrocytoma

AU - Finch, Elizabeth A.

AU - Elton, Scott W.

AU - Huang, Benjamin Y.

AU - Trembath, Dimitri G.

AU - Blatt, Julie

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAF V600E mutations are common in pleomorphic xanthoastrocytomas and provide an additional means for treatment when excision is not possible. Monotherapy with the BRAF V600E inhibitor vemurafenib has only been reported in a small number of cases and mostly in adults. We present the case of a 16-year-old male who responded to vemurafenib monotherapy initially and had an additional response to vemurafenib following progression after a brief time off the medication.

AB - Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAF V600E mutations are common in pleomorphic xanthoastrocytomas and provide an additional means for treatment when excision is not possible. Monotherapy with the BRAF V600E inhibitor vemurafenib has only been reported in a small number of cases and mostly in adults. We present the case of a 16-year-old male who responded to vemurafenib monotherapy initially and had an additional response to vemurafenib following progression after a brief time off the medication.

UR - http://www.scopus.com/inward/record.url?scp=85059307999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059307999&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001395

DO - 10.1097/MPH.0000000000001395

M3 - Article

C2 - 30601402

AN - SCOPUS:85059307999

SN - 1077-4114

VL - 42

SP - 152

EP - 155

JO - Journal of pediatric hematology/oncology

JF - Journal of pediatric hematology/oncology

IS - 2

ER -

Long-Term Efficacy of Single-Agent Vemurafenib for Pleomorphic Xanthoastrocytoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this